Prosecution Insights
Last updated: November 20, 2026
Application No. 18/853,458

CHIMERIC ANTIGEN RECEPTOR T CELLS AND METHODS OF USE THEREOF

Non-Final OA §102§103§112
Filed
Oct 02, 2024
Priority
Apr 06, 2022 — provisional 63/327,890 +2 more
Examiner
GRABER, JAMES J
Art Unit
1631
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of Colorado
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
1y 8m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
93 granted / 200 resolved
-13.5% vs TC avg
Strong +58% interview lift
Without
With
+57.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
60 currently pending
Career history
250
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
35.5%
-4.5% vs TC avg
§102
16.5%
-23.5% vs TC avg
§112
29.5%
-10.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 200 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action This action is in response to the papers filed September 23, 2026. Election/Restrictions Applicant’s reply filed 09/23/2026 to the Requirement for Restriction/Election mailed 07/23/2026 is acknowledged. Applicant elected without traverse: Group 1, claims 1-15, drawn to a cell comprising a chimeric antigen receptor (CAR), and compositions comprising thereof; and the CAR polypeptide according to SEQ ID NO: 84. Claims 16-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 09/23/2026. Claim Listing The instant claim listing was filed on 05/27/2025. Claims 1-18 are pending. Claims 16-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Claims 1-15 are under examination. Priority The instant application 18/853,458 was filed on 10/02/2024. This application is a national stage of international application PCT/US2023/065479 filed 04/06/2023, claiming priority based on U.S. Provisional Patent Application Nos. 63/339,100, filed 05/06/2022, and 63/327,890 filed 04/06/2022. Information Disclosure Statement The information disclosure statements (IDS) submitted on 09/23/2026 and 05/19/2025 have been considered. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, or by applicant in an information disclosure statement (IDS), they have not been considered. Claim Objections Claims 1-2 are objected to because of the following informalities: In claim 1, line 7, the term “MHCI” should be “MHC Class I (MHCI)” instead. In claim 2, line 3, the term “MHC-I” should be “MHCI” instead. Appropriate action is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5, 7, 8 and 11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 5 recites the human B2ML comprises “the amino acid sequence of SEQ ID NO: 73.” Claim 7 recites the human B2M comprises “the amino acid sequence of SEQ ID NO: 75.” Claim 8 recites an HLA-A comprising “the amino acid sequence of SEQ ID NO: 76.” Claim 11 recites the CD8 binding domain comprises “the amino acid sequence of SEQ ID NO: 77.” The above recitations are indefinite because SEQ ID NOs: 73, 75, 76 and 77 are not amino acid sequences. Therefore, one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Claim Rejections - 35 USC § 102 & 103 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 12 and 14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO 2019/073248 A1 to Pulé et al. Pulé is relevant prior art for disclosing a cell comprising an MHC Class I CAR comprising two non-covalently linked polypeptide chains, α chain (MHCI) and β2-microglobulin (β2m), and loaded with a cognate peptide recognized by a TCR, wherein the β2m is connected to a transmembrane domain via a bridge sequence and an endodomain which acts to transmit intracellular signals to the cell, wherein the endodomain comprises at least one costimulatory domain (41BB/CD28) and an intracellular signaling domain (CD3ζ). See, pages 7-8 and Figures 1-5. PNG media_image1.png 622 908 media_image1.png Greyscale PNG media_image2.png 474 660 media_image2.png Greyscale Pulé further discloses the B2M polypeptide may be engineered to include the cognate peptide linked to the B2M so that the MHC Class I exclusively presents the linked cognate peptide. See, page 10, lines 17-22. The B2M polypeptide comprises a B2M leader sequence (MSRSVALAVLALLSLSGLEA). See, page 12, lines 1-20. For these reasons, claim 1 is anticipated by Pulé. Regarding claim 12, the cell is a T cell. See, page 4, lines 29-30. Regarding claim 14, Pulé further discloses pharmaceutical compositions comprising the cell and a pharmaceutically acceptable carrier. See, pages 34-35. Claims 3-8, 13 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over Pulé, as applied above. Regarding claim 3, Pulé teaches the invention is used for treating autoimmune diseases, allergies and graft-vs-host rejection. See, page 36, lines 12-13. Pulé does not teach the cognate peptide is isolated or derived from an antigen of an autoimmune disease or a chronic inflammatory disease, as claimed However, antigens of an autoimmune disease or a chronic inflammatory disease that may be loaded on an MHC Class I molecule were known in the art, prior to the effective filing date of the instantly claimed invention. Official Notice taken, if necessary. Therefore, prior to the effective filing date of the instantly claimed invention, it would have been prima facie obvious to one of ordinary skill in the art to substitute the cognate peptide of Pulé with an antigen of an autoimmune disease or a chronic inflammatory disease, as previously known in the art, with a reasonable expectation of success in order to treat an autoimmune disease, allergy or graft-vs-host rejection, and the simple substitution of one known element for another would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Regarding claims 4-8, the claims recite that each component of the CAR is derived from human sequences, as opposed to nonhuman animal species. Pulé does not expressly teach that each component of the CAR is human in origin, as claimed. However, human sequences for each component of the CAR were known in the art prior to the effective filing date of the instantly claimed invention. Official Notice taken, if necessary. Therefore, prior to the effective filing date of the instantly claimed invention, it would have been prima facie obvious to one of ordinary skill in the art to substitute the sequence of each component of the CAR, as found in Pulé, with a corresponding humanized sequence, as previously known in the art, with a reasonable expectation of success because humanized sequences would be less immunogenic when the CAR is introduced into a human body, and the simple substitution of one known element for another would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Regarding claim 13, Pulé teaches the cell is a T cell (page 4, lines 29-30) or, more specifically, a cytotoxic T cell (page 29, lines 6-10). Pulé does not expressly teach that the cytotoxic T cells express CD8, as claimed. "[I]n considering the disclosure of a reference, it is proper to take into account not only specific teachings of the reference but also the inferences which one skilled in the art would reasonably be expected to draw therefrom." In re Preda, 401 F.2d 825, 826, 159 USPQ 342, 344 (CCPA 1968). See, MPEP 2144.01. In this case, cytotoxic T cells comprise a functional T-cell receptor (TCR) for targeting other cells, e.g., cancer cells, and CD8 serves as a co-receptor for the TCR. Therefore, one of ordinary skill in the art would have reasonably inferred that the cytotoxic T cells of Pulé are CD8+ T cells, as claimed. For these reasons, the limitations of claim 13 would have been prima facie obvious over the prior art. Regarding claim 15, the claim further recites a pharmaceutical composition comprising about 1.0 × 105 to about 1.0 × 109 cells. Pulé does not teach the range of about 1.0 × 105 to about 1.0 × 109 cells, as claimed. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). MPEP 2144.05 further instructs that, generally, differences in concentration (amount) will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration (amount) is critical. In this case, as set forth above, a pharmaceutical composition comprising the cells, generally, is taught by the prior art in Pulé, and there is no evidence of record that the instantly claimed range is critical. Moreover, prior to the effective filing date of the instantly claimed invention, one of ordinary skill in the art would have recognized that the amount of cells in the pharmaceutical composition is a result-effective variable effecting the outcome of treatment when the pharmaceutical composition is administered to a subject in need thereof. Therefore, one of ordinary skill in the art would have been led to optimize the amount of cells through routine experimentation in order to arrive at a more effective therapy. For these reasons, absent a secondary consideration, the claimed range of about 1.0 × 105 to about 1.0 × 109 cells would have been prima facie obvious over the prior art. Claims 1, 12 and 14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO 2019/094847 A1 to Norville et al. Norville is relevant prior art for disclosing a major histocompatibility complex-based chimeric receptor (MHC-CAR) for use in targeting autoreactive immune cells. See, Abstract. The MHC-CAR is expressed by a T cell and comprises an ectodomain of an MHC linked to an antigenic peptide of an autoimmune disease and an intracellular domain of a CAR molecule. In particular, the MHC-CAR comprises an ectodomain, a transmembrane domain, at least one costimulatory domain and a cytoplasmic signaling domain, wherein the ectodomain comprises a beta-2 microglobulin signal peptide, an antigenic peptide, at least one linker domain, a beta-2 microglobulin, an MHC Class I molecule such as HLA-A, and a stalk/hinge domain. See, pages 1-3, and Figures 2, 8B and 9. PNG media_image3.png 331 935 media_image3.png Greyscale The MHC class I molecule is a human HLA-A molecule, a human HLA-B molecule, or a human HLA-C molecule (page 11); the beta-2-microglobulin is human beta-2-microglobulin (page 37); the beta-microglobulin signal peptide has the amino acid sequence MSRSVALAVLALLSLS-GLEA (page 35); and the sequences of one or more of the components of the MHC-CAR are obtained form a human cell (page 52). The T cells is a cytotoxic T cell (pg. 4) or a CD8+ T cell (pg. 89-90). Norville further discloses pharmaceutical compositions comprising the MHC-CAR cells and a pharmaceutically acceptable carrier (page 5), For these reasons, claims 1-9, 12-14 are anticipated by Norville. Claim 15 is rejected under 35 U.S.C. 103 as being unpatentable over Norville, as applied above. Regarding claim 15, the claim further recites a pharmaceutical composition comprising about 1.0 × 105 to about 1.0 × 109 cells. Norville does not teach the range of about 1.0 × 105 to about 1.0 × 109 cells, as claimed. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). MPEP 2144.05 further instructs that, generally, differences in concentration (amount) will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration (amount) is critical. In this case, as set forth above, a pharmaceutical composition comprising the cells, generally, is taught by the prior art in Norville, and there is no evidence of record that the instantly claimed range is critical. Moreover, prior to the effective filing date of the instantly claimed invention, one of ordinary skill in the art would have recognized that the amount of cells in the pharmaceutical composition is a result-effective variable effecting the outcome of treatment when the pharmaceutical composition is administered to a subject in need thereof. Therefore, one of ordinary skill in the art would have been led to optimize the amount of cells through routine experimentation in order to arrive at a more effective therapy. For these reasons, absent a secondary consideration, the claimed range of about 1.0 × 105 to about 1.0 × 109 cells would have been prima facie obvious over the prior art. Claims 10-11 are rejected under 35 U.S.C. 103 as being unpatentable over Norville, as applied above; in view of Wooldridge et al. (2007) “Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region” European journal of immunology, 37(5), 1323-1333. Regarding claims 10-11, the claims recite that the HLA-A comprises at least one mutation in the CD8 binding domain. Norville does not teach the HLA-A comprises at least one mutation in the CD8 binding domain, as claimed. Woodridge is relevant prior art for teaching that CD8 facilitates antigen recognition by binding to the invariant domains of peptide-MCH Class I complexes (pMHCI), and a mutation in a CD8 binding domain of HLA-A enhances CD8 binding by about 50% without altering TCR/pMHCI interactions. See, Abstract. Therefore, prior to the effective filing date of the instantly claimed invention, it would have been prima facie obvious to one of ordinary skill in the art to modify the invention of Norville by introducing a mutation into a CD8 binding domain of HLA-A, in view of Woodridge, with a reasonable expectation of success in order to enhance CD8 binding without altering TCR/pMHCI interactions. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES J GRABER whose telephone number is (571)270-3988. The examiner can normally be reached Monday-Thursday: 9:00 am - 4:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James D Schultz can be reached at (571)272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES JOSEPH GRABER/Examiner, Art Unit 1631
Read full office action

Prosecution Timeline

Oct 02, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760278
METHOD FOR OBTAINING ENDOMETRIAL MESENCHYMAL STEM CELLS FROM HUMAN MENSTRUAL BLOOD
4y 0m to grant Granted Oct 13, 2026
Patent 12747440
Antisense oligonucleotides for the treatment of Stargardt disease
1y 11m to grant Granted Sep 29, 2026
Patent 12741034
COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS
1y 10m to grant Granted Sep 22, 2026
Patent 12735711
TARGETING THE HUMAN CCR5 LOCUS AS A SAFE HARBOR FOR THE EXPRESSION OF THERAPEUTIC PROTEINS
3y 9m to grant Granted Sep 15, 2026
Patent 12668612
ONCOLYTIC NON-HUMAN ADENOVIRUSES AND USES THEREOF
4y 5m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
99%
With Interview (+57.6%)
3y 9m (~1y 8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 200 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month